anlotinib + capecitabine + sintilimab + vinorelbine

This is a combination regimen consisting of four distinct anti-cancer agents: - **Anlotinib** is a multi-targeted small molecule tyrosine kinase inhibitor that blocks angiogenesis and tumor growth by inhibiting vascular endothelial growth factor receptors (VEGFR1/2/3), platelet-derived growth factor receptors (PDGFRα/β), fibroblast growth factor receptors (FGFR1–4), and c-Kit. It disrupts multiple signaling pathways involved in tumor proliferation, angiogenesis, and metastasis[1][2][3][5]. - **Capecitabine** is an oral prodrug of 5-fluorouracil (5-FU) that inhibits thymidylate synthase, interfering with DNA synthesis in rapidly dividing cells. - **Sintilimab** is a monoclonal antibody immune checkpoint inhibitor targeting programmed cell death protein 1 (PD-1), thereby enhancing T-cell mediated anti-tumor immunity. - **Vinorelbine** is a semisynthetic vinca alkaloid chemotherapy agent that inhibits microtubule assembly by binding to tubulin, blocking mitosis and inducing apoptosis in cancer cells[6][7][8][9][10]. This combination leverages targeted therapy, immunotherapy, and cytotoxic chemotherapy for synergistic anti-tumor effects. It has been investigated primarily for advanced or refractory solid tumors such as non-small cell lung cancer.